<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05088070</url>
  </required_header>
  <id_info>
    <org_study_id>SPH3348-101</org_study_id>
    <nct_id>NCT05088070</nct_id>
  </id_info>
  <brief_title>Clinical Study of SPH3348 Tablets, a c-Met Inhibitor, in Patients With Advanced Solid Tumors</brief_title>
  <official_title>Phase I Clinical Study of SPH3348 Tablets, a c-Met Inhibitor, in Patients With Advanced Solid Tumors With c-Met Abnormalities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Pharmaceuticals Holding Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Pharmaceuticals Holding Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 clinical trial of SPH3348 tablets, a c-Met inhibitor, in patients with&#xD;
      advanced solid tumors with c-Met abnormalities. A modified 3 + 3 design was adopted in&#xD;
      patients with advanced solid tumors with c-Met abnormalities, with a total of 6 dose groups,&#xD;
      in which accelerated dose escalation was adopted for the lowest dose group, and 3 + 3 dose&#xD;
      escalation was adopted from the second dose group. The primary objective was to evaluate the&#xD;
      safety and tolerability of SPH3348 tablets in patients with advanced solid tumors with c-Met&#xD;
      abnormalities.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT)</measure>
    <time_frame>24 days</time_frame>
    <description>Incidence of DLT in all subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>24 days</time_frame>
    <description>Measurement of MTD in all subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentration (Cmax) of SPH 3348.</measure>
    <time_frame>24 days</time_frame>
    <description>To characterize the PK (Pharmacokinetics) of SPH 3348.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum serum concentration (Tmax) SPH 3348.</measure>
    <time_frame>24 days</time_frame>
    <description>To characterize the PK (Pharmacokinetics) of SPH 3348.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC) of SPH 3348.</measure>
    <time_frame>24 days</time_frame>
    <description>To characterize the PK (Pharmacokinetics) of SPH 3348.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t1/2) of SPH 3348.</measure>
    <time_frame>24 days</time_frame>
    <description>To characterize the PK (Pharmacokinetics) of SPH 3348.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>24 days</time_frame>
    <description>Measurement of ORR in all subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>24 days</time_frame>
    <description>Measurement of DCR in all subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission (DOR)</measure>
    <time_frame>24 days</time_frame>
    <description>Measurement of DOR in all subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>24 days</time_frame>
    <description>Measurement of PFS in all subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker expression level</measure>
    <time_frame>24 days</time_frame>
    <description>Evaluate the level of hepatocyte growth factor(HGF).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>SPH 3348 tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 different dosage group of SPH 3348 will be assigned with 16mg, 40mg, 80mg, 160mg, 240mg and 320mg respectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPH 3348</intervention_name>
    <description>2 tablets of 8mg SPH3348 will be orally administered once a day with empty stomach</description>
    <arm_group_label>SPH 3348 tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPH 3348</intervention_name>
    <description>1 tablet of 40mg SPH3348 will be orally administered once a day with empty stomach</description>
    <arm_group_label>SPH 3348 tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPH 3348</intervention_name>
    <description>2 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach</description>
    <arm_group_label>SPH 3348 tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPH 3348</intervention_name>
    <description>4 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach</description>
    <arm_group_label>SPH 3348 tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPH 3348</intervention_name>
    <description>6 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach</description>
    <arm_group_label>SPH 3348 tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPH 3348</intervention_name>
    <description>8 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach</description>
    <arm_group_label>SPH 3348 tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with advanced solid tumors with c-Met abnormalities who have failed standard&#xD;
             of care or are not eligible for standard therapy currently&#xD;
&#xD;
          2. ECOG score of 0 or 1.&#xD;
&#xD;
          3. Patients must have measurable lesion that can be assessed by imaging per RECIST 1.1&#xD;
             criteria.&#xD;
&#xD;
          4. Expected survival &gt; 12 weeks.&#xD;
&#xD;
          5. Patients must have adequate organ function&#xD;
&#xD;
          6. Patients must give informed consent to the study and sign the informed consent form&#xD;
             prior to the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received anti-tumor therapies, including but not limited to chemotherapy, biotherapy,&#xD;
             radiotherapy, targeted therapy, etc., within 4 weeks prior to the first dose of study&#xD;
             drug; received nitrosoureas or mitomycin C within 6 weeks prior to the start of study&#xD;
             drug.&#xD;
&#xD;
          2. Received small molecule tyrosine kinase inhibitors within 2 weeks prior to the first&#xD;
             dose.&#xD;
&#xD;
          3. Received strong CYP3A4 inducers or inhibitors or CYP3A4 substrates with narrow&#xD;
             therapeutic windows within 2 weeks prior to the start of study drug.&#xD;
&#xD;
          4. Patients with active hepatitis B (hepatitis B surface antigen (HBsAg) positive) or&#xD;
             hepatitis C (HCV).&#xD;
&#xD;
          5. Toxicities caused by prior treatments have not recovered to CTCAE Grade ≤ 1 or having&#xD;
             ≥Grade 2 peripheral neuropathy, except for alopecia and other events judged as&#xD;
             tolerable by the investigator.&#xD;
&#xD;
          6. Known allergy to any component of the reference drug.&#xD;
&#xD;
          7. Known drug or alcohol dependence.&#xD;
&#xD;
          8. Received surgical treatment including surgical and interventional procedures within 4&#xD;
             weeks prior to the start of study drug.&#xD;
&#xD;
          9. Patients with brain metastases.&#xD;
&#xD;
         10. Past medical history of interstitial lung disease, drug-induced interstitial lung&#xD;
             disease, radiation pneumonitis which required steroid treatment, or evidence of any&#xD;
             clinically active interstitial lung disease.&#xD;
&#xD;
         11. Acute bacterial, viral, or fungal infection requiring systemic therapy or unexplained&#xD;
             fever (temperature &gt; 38.5 °C) during screening, prior to the first dose.&#xD;
&#xD;
         12. Neurological and psychiatric patients with obvious poor compliance.&#xD;
&#xD;
         13. Any of the following within 6 months prior to signing of informed consent form:&#xD;
             uncontrolled congestive cardiac failure, severe or unstable angina pectoris,&#xD;
             myocardial infarction, stroke, coronary/peripheral artery bypass surgery, pulmonary&#xD;
             embolism.&#xD;
&#xD;
         14. Arrhythmia uncontrolled by medication or sustained QTcB prolongation.&#xD;
&#xD;
         15. Hypertension uncontrolled by medication&#xD;
&#xD;
         16. Participated in other drug clinical studies within 28 days prior to the first dose of&#xD;
             study drug.&#xD;
&#xD;
         17. Women who are pregnant or in lactation period or women/men with childbearing plans.&#xD;
&#xD;
         18. Patients who cannot take oral medication, or have previous surgical history or serious&#xD;
             gastrointestinal diseases such as dysphagia, active gastric ulcer, which may impair&#xD;
             the absorption of the study drug in the investigator's opinion.&#xD;
&#xD;
         19. Other prior or current concomitant malignancies.&#xD;
&#xD;
         20. Patients who are ineligible to participate in this trial for any reason judged by the&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zishu Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affliated Hospital of Bengbu Medical College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Huan Zhou</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affliated Hospital of Bengbu Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zishu Wang</last_name>
    <phone>13955254185</phone>
    <email>wzshahbb@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Huan Zhou</last_name>
    <phone>13665527160</phone>
    <email>zhouhuanbest@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affliated Hospital of Bengbu Medical College</name>
      <address>
        <city>Bengbu</city>
        <state>Anhui</state>
        <zip>233004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huan Zhou</last_name>
    </contact>
    <investigator>
      <last_name>Huan Zhou</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zishu Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 24, 2021</study_first_submitted>
  <study_first_submitted_qc>October 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

